|
 |
Article Review/Hyperlink
|
Gause BL, Sznol M, Kopp WC, Janik JE, et al
Phase 1 study of subcutaneously administered interleukin-2 in
combination with interferon alfa-2a in patients with advanced
cancer
J Clin Oncol
(Aug) 14:2234-2241 1996

The prognosis for patients with advanced renal cancer remains poor.
High dose interleukin-2 has been used in an attempt to induce
remission, but severe toxicity often occurs. In this paper, a low
dose combination of interleukin-2 and interferon alpha-2a are used in
combination subcutaneously to treat patients with renal cell
carcinoma. Partial remission, defined as a 50% decrease in tumor
size for at least 4 weeks was found in 6/25 patients (24%). The
treatment did not prevent side effects, including fatigue, fever, and
nausea/vomiting, but side effects were much less severe than with the
previously used high dose regimens.
The full abstract is
available from the J Clin Oncol at this
site.
Related Folders: |
 |
|
|
|
|